Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from June 17, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 15, 2026 — -4.1% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$41.92 – $43.87Entry zone — fair-value band

$44.33Published — price the day we called it

$48.15Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$42.53Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 14 days.

At window close

-4.1%

realized, from the publication price to the last close inside the window

Peak gain

+16.1%

peak, from the publication price — not a realized return

S&P 500, same window

+2.5%

SPY over the identical days, dividend-adjusted

Window close

$42.53

last close inside the window, ended September 15, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published June 17, 2026

Predicted growth

+10%

over the measurement window

Target price

$48.15

the price the thesis aimed for

Entry zone

$41.92 – $43.87

the fair-value band we waited for

Price at publication

$44.33

published June 17, 2026

Confidence

78%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is growing because its GLP-1 medicines for obesity and diabetes are in high demand. A likely filing in China for an oral version of Wegovy gives a near-term upside chance. Recent problems-a leaked trial dataset and some supply strain-make the outlook less certain. Overall, the setup looks constructive for the next few months if demand holds and headlines do not worsen.

Primary drivers

Strong ongoing demand for GLP-1 medications
China filing for oral Wegovy could drive near-term approval news
Valuation is moderate, making growth feel more defensive
Trial data leak and supply limits make short-term risk visible

How it played out

NVO: target reached in 14 days

Lyra published a short-term thesis for 10% growth from a price of $44.33. The thesis pointed to strong demand for GLP-1 medicines, a possible China filing for oral Wegovy, and a moderate valuation. It also identified a trial data leak and supply limits as risks.

NVO reached the $48.15 target in 14 days. It later peaked at $51.46 on July 29, a gain of 16.1%. The price then fell and ended the window at $42.53. The thesis played out within the window and exceeded its target, although the gain did not hold through the end.

What happened during the window

On July 15, Novo Nordisk said the European Commission had authorized the Wegovy pill for adults with obesity or overweight. On August 4, the company reported that adjusted second-quarter sales had risen 7% at constant exchange rates and raised its full-year outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals